FDA approves Nucletron's Esteya Brachytherapy System for Skin Cancer

Esteya, an electronic Brachytherapy system, from Nucletron, has received 510(k) clearance from the FDA enabling a new treatment option for Skin Cancer. The system relies on a small, high dose rate (HDR) to apply radiation directly to the cancerous site. This direct delivery enables Esteya to focus more therapeutic radiation on the disease target and to minimize radiation to surrounding tissues and organs. Electronic brachytherapy is well-suited for treating skin lesions, such as basal cell or squamous cell carcinoma, achieving a greater than 95 percent cure rate for this technique.